within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD01_Flurazepam;

model Flurazepam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.83,
    Cl = 1.1333333333333334e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0006333333333333333,
    Tlag = 600,
    Vdp = 0.0017,
    k12 = 2.5e-05,
    k21 = 2.5e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Flurazepam</td></tr><tr><td>ATC code:</td><td>N05CD01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>68</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Flurazepam is a long-acting benzodiazepine used as a hypnotic for the treatment of insomnia. It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission. While once widely used for insomnia, its use today is limited due to risks of dependence, next-day sedation, and the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single 30 mg oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Flurazepam;
